Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present ...

google.com·23w

Protagonist And Takeda Report 52-Week Rusfertide Data In <b>Polycythemia Vera</b> - Nasdaq

google.com·23w

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its ... - FinancialContent

google.com·23w

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its ... - Barron&#39;s

google.com·23w

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its ...

google.com·23w

Prelude Therapeutics Presents Data at the 2025 ASH Annual - GlobeNewswire

google.com·23w

Living with blood cancers like multiple myeloma and <b>myelofibrosis</b> can bring new, and often ...

google.com·23w

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Show - GuruFocus

google.com·23w

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of ...

google.com·23w

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide ...

google.com·23w

Rusfertide ASH 2025 VERIFY Data in <b>Polycythemia Vera</b> - Takeda Pharmaceuticals

google.com·23w

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide ...

google.com·23w

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of ...

google.com·23w

Disc Medicine Presents Positive Initial Data from RALLY-MF - GlobeNewswire

google.com·23w

Disc Medicine reports anemia response data from <b>myelofibrosis</b> trial - StreetInsider

google.com·23w

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients ... - Aktiencheck

google.com·23w

Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025

google.com·23w

All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025

google.com·24w

QDX Collaborates with Prelude Therapeutics on Mutant Selective JAK2 JH2 Inhibitor Program

google.com·24w

Regression of Post-Essential Thrombocythaemia <b>Myelofibrosis</b> with Intermittent ... - MDPI

google.com·24w

Log in to enable infinite scrolling